Data / New clinical trials / Moldova
New clinical trials in Moldova: 61 since Nov 2024
The full list. New clinical trials with a site in Moldova: 61 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 1 row a month. The new rows come each week by email, $19 a month.
Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/country/moldova, and every list with its row count and price is at https://specstream.ai/data/lists.json.
Updated October 21, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
61 clinical studies with a site in Moldova were first posted on ClinicalTrials.gov from November 13, 2024 to October 21, 2026; 56 have an industry sponsor and 41 are recruiting or about to. The newest, NCT07885891, was posted on October 21, 2026: Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or... (Wockhardt).
The request: Every new clinical trial with a site in Moldova, with the sponsor, phase, conditions and the listed contact. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.
- 61New trials
- 56Industry sponsored
- 41Recruiting or not yet
- October 21, 2026Latest posted
Newest trials
The newest 61 of 61, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
|---|---|---|---|---|---|---|---|---|---|
| October 21, 2026 | NCT07885891 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Wockhardt | Phase 3 | Not yet recruiting | Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | 324 | Bosnia and Herzegovina, Bulgaria, Croatia, France, Georgia, Greece, India... | clinicaltrials.gov |
| September 3, 2026 | NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft... | SOTIO Biotech a.s. | Phase 1/2 | Not yet recruiting | Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced | 70 | Moldova | clinicaltrials.gov |
| August 13, 2026 | NCT07762027 | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | Assembly Biosciences | Phase 2 | Not yet recruiting | Chronic Hepatitis D Infection | 80 | France, Georgia, Germany, Italy, Moldova, New Zealand, Pakistan, Romania... | clinicaltrials.gov |
| August 12, 2026 | NCT07760831 | A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Moderate to Severe Ulcerative Colitis | 8 | Moldova | clinicaltrials.gov |
| July 21, 2026 | NCT07717671 | VIPPSTAR-G1 Digital Early Intervention for Visual Impairment | Università degli Studi di Brescia | Not applicable | Not yet recruiting | Visual Impairment, Cerebral Visual Impairment, Neurodevelopmental Disorders, Prematurity | 150 | Belgium, Italy, Moldova | clinicaltrials.gov |
| July 9, 2026 | NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | SOTIO Biotech a.s. | Phase 1/2 | Recruiting | Colorectal Cancer (Locally Advanced or Metastatic) | 100 | Moldova, United States | clinicaltrials.gov |
| July 6, 2026 | NCT07684820 | To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment | Expedition Therapeutics, Inc | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 600 | Canada, Georgia, Moldova, United States | clinicaltrials.gov |
| June 17, 2026 | NCT07652294 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | Spyre Therapeutics, Inc. | Phase 2 | Enrolling by invitation | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | Argentina, Australia, Austria, Belgium, Brazil, Chile, Czechia, Georgia... | clinicaltrials.gov |
| April 23, 2026 | NCT07547540 | A Study of LY3971297 in Participants With Heart Failure | Eli Lilly and Company | Phase 1 | Recruiting | Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic | 90 | Japan, Moldova, Netherlands, Romania, United States | clinicaltrials.gov |
| April 16, 2026 | NCT07533955 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis | Jade Biosciences, Inc. | Phase 1 | Recruiting | Rhematoid Arthritis | 36 | Bulgaria, Georgia, Germany, Moldova, Romania, Ukraine | clinicaltrials.gov |
| March 17, 2026 | NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | Biocon Biologics UK PLC | Phase 1 | Recruiting | Melanoma | 120 | Brazil, Chile, Georgia, Moldova, Romania, Serbia, South Africa, Spain, Turkey... | clinicaltrials.gov |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
| March 16, 2026 | NCT07472491 | A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients | GE Healthcare | Phase 2/3 | Recruiting | Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion | 640 | Georgia, Moldova, South Korea, United States | clinicaltrials.gov |
| March 3, 2026 | NCT07444931 | Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD | Tampere Heart Hospital | Observational | Recruiting | Coronary Arterial Disease (CAD), Sudden Cardiac Arrest, Sudden Cardiac Death | 1,500 | Israel, Moldova, Romania | clinicaltrials.gov |
| February 25, 2026 | NCT07433335 | A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis | SciRhom GmbH | Phase 1 | Recruiting | Rheumatoid Arthritis | 27 | Georgia, Moldova, Romania | clinicaltrials.gov |
| February 5, 2026 | NCT07389044 | A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | IntegerBio | Phase 1 | Recruiting | Chronic Hepatitis B Virus Infection | 88 | Hong Kong, Moldova, New Zealand, Ukraine | clinicaltrials.gov |
| January 28, 2026 | NCT07374471 | A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis | Mage Biologics | Phase 1/2 | Recruiting | Ulcerative Colitis (UC) | 100 | Georgia, Moldova, Poland, Ukraine | clinicaltrials.gov |
| January 23, 2026 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 21 | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, Peru... | clinicaltrials.gov |
| December 22, 2025 | NCT07296315 | Confirmatory Clinical Study in Active Ulcerative Colitis | MRM Health NV | Phase 2 | Recruiting | Colitis, Ulcerative | 204 | Czechia, Georgia, Moldova, Poland, Serbia, Ukraine, United States | clinicaltrials.gov |
| November 28, 2025 | NCT07254208 | A Long-term Observational Study in Participants Who Have Received PBGENE-HBV | Precision BioSciences, Inc. | Observational | Enrolling by invitation | Chronic HBV Infection | 45 | Hong Kong, Moldova, New Zealand, United States | clinicaltrials.gov |
| November 21, 2025 | NCT07240571 | Randomized Controlled Trial of a Family-focused Intervention for Caregivers and Young Adolescents (Phase 3 of FLOURISH) | University of Klagenfurt | Not applicable | Recruiting | Adolescent - Emotional Problem, Parent Child Relationship, Family Functioning, Well-Being, Psychological | 1,280 | Moldova, North Macedonia | clinicaltrials.gov |
| November 17, 2025 | NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | Xencor, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 68 | Georgia, Moldova, New Zealand | clinicaltrials.gov |
| November 3, 2025 | NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Hyperlipidemia; Mixed | 78 | Australia, Canada, Georgia, Moldova, New Zealand | clinicaltrials.gov |
| October 9, 2025 | NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Symptomatic Venous Thromboembolism (VTE) | 2,000 | Greece, Malaysia, Moldova, Spain, United States | clinicaltrials.gov |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | China, Georgia, India, Indonesia, Japan, Moldova, Peru, Philippines, South... | clinicaltrials.gov |
| October 6, 2025 | NCT07207954 | Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | Lifordi Immunotherapeutics, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 176 | Australia, Georgia, Moldova, Poland, Ukraine | clinicaltrials.gov |
| September 22, 2025 | NCT07185009 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative... | Sanofi | Phase 3 | Recruiting | Ulcerative Colitis | 751 | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
| September 22, 2025 | NCT07184996 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | Sanofi | Phase 3 | Recruiting | Ulcerative Colitis | 980 | Argentina, Australia, Austria, Bulgaria, Canada, China, Czechia, France... | clinicaltrials.gov |
| September 22, 2025 | NCT07184944 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase 3 | Recruiting | Crohn's Disease | 751 | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia... | clinicaltrials.gov |
| September 22, 2025 | NCT07184931 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase 3 | Recruiting | Crohn's Disease | 980 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
| August 29, 2025 | NCT07148414 | A Study of SPY072 in Rheumatic Disease | Spyre Therapeutics, Inc. | Phase 2 | Active not recruiting | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA... | 285 | Bulgaria, Czechia, Georgia, Moldova, Poland, Spain, Ukraine, United States | clinicaltrials.gov |
| August 27, 2025 | NCT07142811 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Vir Biotechnology, Inc. | Phase 2 | Active not recruiting | Viral Hepatitis | 100 | Belgium, Bulgaria, France, Germany, Moldova, Netherlands, Pakistan, Romania... | clinicaltrials.gov |
| August 19, 2025 | NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Non-Small Cell Lung Cancer | 20 | Bosnia and Herzegovina, Bulgaria, Moldova | clinicaltrials.gov |
| August 8, 2025 | NCT07113522 | A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease | Mirador Therapeutics, Inc. | Phase 2 | Recruiting | Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease | 140 | Canada, Georgia, Moldova, Ukraine, United States | clinicaltrials.gov |
| August 8, 2025 | NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People... | BioNTech SE | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer | 880 | Australia, China, Germany, Italy, Moldova, Poland, Spain, Turkey (Türkiye)... | clinicaltrials.gov |
| July 31, 2025 | NCT07096193 | Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus | Gilead Sciences | Phase 1/2 | Recruiting | Chronic Hepatitis Delta | 200 | Bulgaria, Germany, Italy, Moldova, Romania, South Korea, Taiwan, Turkey... | clinicaltrials.gov |
| July 29, 2025 | NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | argenx | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 160 | Argentina, Austria, Brazil, Bulgaria, China, Colombia, Czechia, Denmark... | clinicaltrials.gov |
| July 4, 2025 | NCT07052032 | An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis | Candid Therapeutics | Phase 1 | Active not recruiting | Rheumatoid Arthritis | 47 | Moldova, Ukraine | clinicaltrials.gov |
| June 29, 2025 | NCT07042945 | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) | Merck Sharp & Dohme LLC | Phase 1 | Completed | HIV Infection | 15 | Moldova, Romania | clinicaltrials.gov |
| June 25, 2025 | NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | Atea Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | 880 | Egypt, France, Germany, Greece, India, Malaysia, Moldova, Pakistan, Poland... | clinicaltrials.gov |
| June 10, 2025 | NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Spyre Therapeutics, Inc. | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil... | clinicaltrials.gov |
| May 30, 2025 | NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | AstraZeneca | Phase 1/2 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 152 | Belgium, Brazil, China, France, Georgia, Germany, Italy, Japan, Malaysia... | clinicaltrials.gov |
| May 20, 2025 | NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)... | 85 | Georgia, Greece, Moldova, Poland, Spain, Ukraine, United Kingdom | clinicaltrials.gov |
| May 16, 2025 | NCT06975722 | A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis | Sanofi | Phase 2 | Active not recruiting | Ulcerative Colitis | 105 | Australia, China, Czechia, France, Germany, Hungary, Japan, Moldova, Poland... | clinicaltrials.gov |
| May 9, 2025 | NCT06963710 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg... | Aligos Therapeutics | Phase 2 | Active not recruiting | Chronic Hepatitis B Infection | 200 | Bulgaria, Canada, China, France, Hong Kong, Italy, Moldova, New Zealand... | clinicaltrials.gov |
| May 8, 2025 | NCT06962033 | PRIDE III Prison Interventions and HIV Prevention Collaboration | Yale University | Not applicable | Recruiting | Hiv, Opioid Use | 300 | Georgia, Kyrgyzstan, Moldova, Tajikistan, United States | clinicaltrials.gov |
| April 8, 2025 | NCT06917404 | A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult... | Paradigm Biopharmaceuticals Ltd. | Phase 3 | Active not recruiting | Osteoarthritis, Knee | 466 | Australia, Hong Kong, Moldova, United States | clinicaltrials.gov |
| April 2, 2025 | NCT06907290 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Mirum Pharmaceuticals, Inc. | Phase 2/3 | Active not recruiting | Chronic Hepatitis D Infection | 150 | Australia, Bulgaria, Canada, Georgia, Israel, Moldova, New Zealand, Pakistan... | clinicaltrials.gov |
| March 30, 2025 | NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Vir Biotechnology, Inc. | Phase 3 | Active not recruiting | Viral Hepatitis | 124 | Canada, Georgia, Germany, Moldova, New Zealand, Pakistan, Romania, Ukraine... | clinicaltrials.gov |
| March 30, 2025 | NCT06902519 | Study of GS-0151 in Participants With Rheumatoid Arthritis | Gilead Sciences | Phase 1 | Active not recruiting | Rheumatoid Arthritis | 65 | Georgia, Germany, Moldova, Poland, Spain, United States | clinicaltrials.gov |
| March 27, 2025 | NCT06899061 | Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib | AstraZeneca | Phase 1 | Active not recruiting | Advanced Solid Malignancies | 41 | Bulgaria, Moldova, Romania | clinicaltrials.gov |
| February 27, 2025 | NCT06850727 | Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis | Odyssey Therapeutics, Inc. | Phase 2 | Recruiting | Ulcerative Colitis (UC), UC - Ulcerative Colitis | 57 | Australia, Austria, Canada, Czechia, Jordan, Lithuania, Moldova, New Zealand... | clinicaltrials.gov |
| February 24, 2025 | NCT06842186 | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity | Wave Life Sciences USA, Inc. | Phase 1/2 | Recruiting | Overweight and Obesity | 400 | Moldova, Romania, United Kingdom, United States | clinicaltrials.gov |
| February 19, 2025 | NCT06833749 | Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | KeyBioscience AG | Phase 2 | Recruiting | Osteoarthritis in the Knee, Obesity | 600 | Czechia, Denmark, Hong Kong, Moldova, Poland, Romania | clinicaltrials.gov |
| February 14, 2025 | NCT06827236 | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another... | BioNTech SE | Phase 1/2 | Recruiting | Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer | 380 | Australia, Canada, China, France, Georgia, Italy, Moldova, Spain, Turkey... | clinicaltrials.gov |
| February 4, 2025 | NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and... | Boehringer Ingelheim | Phase 1 | Active not recruiting | Head and Neck Squamous Cell Carcinoma | 91 | Australia, Brazil, Bulgaria, France, Georgia, Germany, Hungary, Italy, Japan... | clinicaltrials.gov |
| January 29, 2025 | NCT06799520 | A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Active not recruiting | Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS) | 30 | Bulgaria, Moldova, Romania, Spain | clinicaltrials.gov |
| January 28, 2025 | NCT06797791 | Assessment of Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation (cTBS) Effects in Generalized Epilepsy Patients. | Universitatea de Stat de Medicina si Farmacie Nicolae Testemiţanu | Not applicable | Completed | Generalized Epilepsy | 14 | Moldova | clinicaltrials.gov |
| January 23, 2025 | NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | Janssen Research & Development, LLC | Phase 1 | Enrolling by invitation | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes... | 120 | Australia, Belgium, Denmark, France, Georgia, Greece, Israel, Japan, Moldova... | clinicaltrials.gov |
| January 20, 2025 | NCT06784349 | ALN-APOC3 in Adult Participants With Dyslipidemia | Regeneron Pharmaceuticals | Phase 1 | Completed | Dyslipidemia | 32 | Moldova | clinicaltrials.gov |
| November 13, 2024 | NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in... | mAbxience Research S.L. | Phase 3 | Active not recruiting | Non Squamous Non Small Cell Lung Cancer | 726 | Armenia, Bosnia and Herzegovina, Brazil, Georgia, Greece, Italy, Japan, Jordan... | clinicaltrials.gov |
Sponsors posting most
| Sponsor | New trials | Latest |
|---|---|---|
| Sanofi | 5 | September 22, 2025 |
| Spyre Therapeutics, Inc. | 3 | June 17, 2026 |
| SOTIO Biotech a.s. | 2 | September 3, 2026 |
| Boehringer Ingelheim | 2 | March 16, 2026 |
| Merck Sharp & Dohme LLC | 2 | January 23, 2026 |
| Regeneron Pharmaceuticals | 2 | October 9, 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | October 7, 2025 |
| Vir Biotechnology, Inc. | 2 | August 27, 2025 |
| BioNTech SE | 2 | August 8, 2025 |
| Gilead Sciences | 2 | July 31, 2025 |
| AstraZeneca | 2 | May 30, 2025 |
| Wockhardt | 1 | October 21, 2026 |
| Assembly Biosciences | 1 | August 13, 2026 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 | August 12, 2026 |
| Università degli Studi di Brescia | 1 | July 21, 2026 |
| Expedition Therapeutics, Inc | 1 | July 6, 2026 |
| Eli Lilly and Company | 1 | April 23, 2026 |
| Jade Biosciences, Inc. | 1 | April 16, 2026 |
| Biocon Biologics UK PLC | 1 | March 17, 2026 |
| GE Healthcare | 1 | March 16, 2026 |
Conditions
| Condition group | New trials | Latest |
|---|---|---|
| Colitis, Ulcerative | 9 | June 17, 2026 |
| Arthritis, Rheumatoid | 7 | February 25, 2026 |
| Inflammatory Bowel Diseases | 4 | June 17, 2026 |
| Hepatitis B, Chronic | 3 | February 5, 2026 |
| Crohn Disease | 3 | September 22, 2025 |
| Hepatitis D | 3 | August 27, 2025 |
| Hepatitis D, Chronic | 3 | August 27, 2025 |
| Carcinoma, Non-Small-Cell Lung | 3 | August 19, 2025 |
| Colitis | 2 | June 17, 2026 |
| Neoplasms | 2 | March 17, 2026 |
| Hepatitis B | 2 | February 5, 2026 |
| Lupus Erythematosus, Systemic | 2 | January 23, 2026 |
| Hepatitis | 2 | August 27, 2025 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | May 20, 2025 |
| Osteoarthritis | 2 | April 8, 2025 |
| Obesity | 2 | February 24, 2025 |
| Sarcoma | 1 | September 3, 2026 |
| Osteosarcoma | 1 | September 3, 2026 |
| Vision Disorders | 1 | July 21, 2026 |
| Blindness, Cortical | 1 | July 21, 2026 |
| Neurodevelopmental Disorders | 1 | July 21, 2026 |
| Premature Birth | 1 | July 21, 2026 |
| Colorectal Neoplasms | 1 | July 9, 2026 |
| Neoplasm Metastasis | 1 | July 9, 2026 |
| Pulmonary Disease, Chronic Obstructive | 1 | July 6, 2026 |
By phase
| Phase | New trials | Latest |
|---|---|---|
| Phase 1 | 19 | August 12, 2026 |
| Phase 3 | 13 | October 21, 2026 |
| Phase 2 | 12 | August 13, 2026 |
| Phase 1/2 | 9 | September 3, 2026 |
| Not applicable | 4 | July 21, 2026 |
| Phase 2/3 | 2 | March 16, 2026 |
| Observational | 2 | March 3, 2026 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.